Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06480240 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by OBI Pharma.

Active
Registry status
Phase 1
Development phase
117
Enrollment target
8
Study locations

NCT06480240 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by OBI Pharma. The registered enrollment target is 117 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (39% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06480240, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by OBI Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
117 participants
Enrollment target
8
Study locations

Study Summary

This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-992 (Anti-TROP2 antibody drug conjugate, anti-TROP2 monoclonal antibody-cleavable peptide linker-exatecan) as monotherapy. Part B (Cohort Expansion) is intended to further characterize the safety and preliminary clinical activity profile of the RP2D of OBI-992 in subjects with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG OBI-992

Study Locations (8)

California

  • California Clinical Trials Medical Group (CCTMG) - Glendale
  • Scripps Green Hospital - La Jolla

Texas

  • The University of Texas MD Anderson Cancer Center - Houston
  • NEXT Oncology - San Antonio

Michigan

  • Karmanos Cancer Institute - Detroit

Virginia

  • NEXT Virginia - Fairfax

Xindian District

  • Taipei Tzu Chi Hospital - New Taipei City

Zhonghe District

  • Taipei Medical University - Shuang Ho Hospital - New Taipei City

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2024-06-12
Est. Completion 2027-06
Phase Phase 1

Sponsor

OBI Pharma

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06480240

The ClinicalTrials.gov registry entry for NCT06480240 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (39% lower). The listed sponsor is OBI Pharma, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which OBI-992 is the first listed.

NCT06480240 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Texas, Michigan.

Frequently Asked Questions

What is clinical trial NCT06480240 about?

NCT06480240 is a clinical study titled "A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors". This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-992 (Anti-TROP2 antibody drug conjugate, anti-TROP2 monoclonal antibody-cleavable peptide linker-exatecan) as monotherapy. Part B (Cohort Expansion) i...

What is the current status of trial NCT06480240?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2024-06-12. Estimated completion is 2027-06.

What conditions does trial NCT06480240 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06480240?

The interventions under investigation include: OBI-992 (DRUG).

Who is sponsoring clinical trial NCT06480240?

This trial is sponsored by OBI Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06480240 being conducted?

This trial has 8 study locations across California, Michigan, Texas, Virginia, Xindian District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.